Allergy Therapeutics has announced new senior appointments and the expansion of the R&D and clinical teams in-line with its wider strategic growth plans at its Worthing headquarters. This is an important period for Allergy Therapeutics, as it invests in a variety of key programmes and platforms in order to drive significant value upside and we consider the continued investment in R&D and clinical development teams – the R&D team has doubled by headcount since 2016 – re
